Nothing can change the facts that we are playing in a $2 Billion CNS market now, simple and easy. We are in the right direction to have $160 - $180M revenue annually just from CNS Adderall IR and Aderall XR. All those opiods drugs combined annual sale was $1 Billion market. So, it was a smart move. Meanwhile, we still have Opiods in our portofolio like SequestOx, Generic Oxycontin, etc but for now we have our focus on CNS. We put them in back burner for now. It is totally logical.
Numbers Never Lie!
Stay long and strong
News 
Market Data 
Discover 
